Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

58.01 -2.96 (-4.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Tempus AI Stock Rockets After Introduction Of Liquid Biopsy Assay For Cancer Treatment Monitoring: Retail Hopes For A 20% Rally
The company stated that the assay, currently available for research use, will be clinically available later this year. 
Via Stocktwits
Topics Artificial Intelligence
Tempus AI Stock Is Surging Today: What Investors Are Watching
Tempus AI Inc (NASDAQ:TEM) shares are moving higher Monday after the company introduced a new program to monitor immunotherapy response for patients with advanced cancer. 
Via Benzinga
Topics Artificial Intelligence
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
From Tempus AI, Inc.
Via Business Wire
Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Tempus AI Stock: Buy the Dip, or Is the Short-Seller Right?
Via The Motley Fool
Topics Artificial Intelligence
Why Tempus AI Stock Plummeted This Week
Via The Motley Fool
Topics Artificial Intelligence
Real-World Deployments Signal AI Healthcare Is Ready for Scale
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:BTAI),(OTCPK:HWAIF),(OTCQX:WHTCF) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tempus: Short Seller Attack Brings Golden Opportunity Cathie Wood Was Waiting For
ARK ETFs' Cathie Wood buys 251,080 shares of Tempus AI, a precision medicine company, amid short seller attack and bullish technical indicators.>ARK ETFs' Cathie Wood buys 251,080 shares of Tempus AI,... 
Via Benzinga
Topics Artificial Intelligence
Nvidia, Apple, Amazon, Tempus AI, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The Dow Jones Industrial Average falling 0.6% to 42,098.70 and the S&P 500 slipping by a similar margin to 5,888.55 on Wednesday. 
Via Benzinga
Topics Artificial Intelligence Stocks
Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
Cathie Wood Ditches $5.6M More Tesla While Elon Musk Quits Government Role — Doubles Down On AI Stock Under Attack By Short Sellers
ARK Invest, led by Cathie Wood, made significant trades involving Tesla and Tempus AI amid insider sales and short seller scrutiny. $5.6 million in Tesla shares sold, $13.36 million in Tempus AI shares... 
Via Benzinga
Topics Artificial Intelligence
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation – TEM
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Tempus AI, Inc. – TEM
From Pomerantz LLP
Via GlobeNewswire
A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today
Via The Motley Fool
Topics Artificial Intelligence Stocks
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Artificial Intelligence Stock Tempus AI Is Tumbling Today
An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward stock purchased by a high-profile politician. 
Via The Motley Fool
Topics Artificial Intelligence
Top movers analysis in the middle of the day on 2025-05-28: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Tempus AI Stock Sinks On Spruce Point’s Short Report
The report stated that Tempus AI’s management and board members have a history of promoting “disruptive technology companies” and cashing out early. 
Via Stocktwits
Topics Artificial Intelligence
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
Via Benzinga
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King'
Spruce Point Capital Management has announced a new short position against Tempus AI Inc (NASDAQ:TEM). The short seller on Wednesday raised concerns around the company's management team and... 
Via Benzinga
Topics Artificial Intelligence
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
From Tempus AI, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
From Ambry Genetics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.